SE0102627L - Vektorer motståndskraftiga mot metylering - Google Patents
Vektorer motståndskraftiga mot metyleringInfo
- Publication number
- SE0102627L SE0102627L SE0102627A SE0102627A SE0102627L SE 0102627 L SE0102627 L SE 0102627L SE 0102627 A SE0102627 A SE 0102627A SE 0102627 A SE0102627 A SE 0102627A SE 0102627 L SE0102627 L SE 0102627L
- Authority
- SE
- Sweden
- Prior art keywords
- host cell
- vectors
- methylation
- receiver host
- receiver
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Emergency Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102627A SE0102627L (sv) | 2001-07-27 | 2001-07-27 | Vektorer motståndskraftiga mot metylering |
EP02741568A EP1419257A1 (en) | 2001-07-27 | 2002-07-08 | Methylation resistant vectors |
MXPA04000651A MXPA04000651A (es) | 2001-07-27 | 2002-07-08 | Vectores resistentes a metilacion. |
CA002453372A CA2453372A1 (en) | 2001-07-27 | 2002-07-08 | Methylation resistant vectors |
PCT/SE2002/001121 WO2003012112A1 (en) | 2001-07-27 | 2002-07-08 | Methylation resistant vectors |
JP2003517286A JP2004536616A (ja) | 2001-07-27 | 2002-07-08 | メチル化耐性ベクター |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0102627A SE0102627L (sv) | 2001-07-27 | 2001-07-27 | Vektorer motståndskraftiga mot metylering |
Publications (3)
Publication Number | Publication Date |
---|---|
SE0102627D0 SE0102627D0 (sv) | 2001-07-27 |
SE518759C2 SE518759C2 (sv) | 2002-11-19 |
SE0102627L true SE0102627L (sv) | 2002-11-19 |
Family
ID=20284952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0102627A SE0102627L (sv) | 2001-07-27 | 2001-07-27 | Vektorer motståndskraftiga mot metylering |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1419257A1 ( ) |
JP (1) | JP2004536616A ( ) |
CA (1) | CA2453372A1 ( ) |
MX (1) | MXPA04000651A ( ) |
SE (1) | SE0102627L ( ) |
WO (1) | WO2003012112A1 ( ) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
CN108635367B (zh) | 2011-08-30 | 2020-08-21 | 阿斯泰克斯制药公司 | 地西他滨衍生物制剂 |
FR2981946B1 (fr) * | 2011-10-28 | 2015-02-20 | Lfb Biotechnologies | Unites de transcription et leur utilisation dans des vecteurs d'expression (yb2/0) |
AU2016287585B2 (en) | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5552277A (en) * | 1994-07-19 | 1996-09-03 | The Johns Hopkins University School Of Medicine | Genetic diagnosis of prostate cancer |
WO1996012008A1 (en) * | 1994-10-13 | 1996-04-25 | Merck & Co., Inc. | Synthesis of methylase-resistant genes |
US6783933B1 (en) * | 1999-09-15 | 2004-08-31 | The Johns Hopkins University School Of Medicine | CACNA1G polynucleotide, polypeptide and methods of use therefor |
WO2001026536A2 (en) * | 1999-10-13 | 2001-04-19 | The Johns Hopkins University School Of Medicine | Methods of diagnosing and treating hepatic cell proliferative disorders |
CA2386476A1 (en) * | 1999-10-18 | 2001-04-26 | Emory University | Tms1 compositions and methods of use |
-
2001
- 2001-07-27 SE SE0102627A patent/SE0102627L/ not_active IP Right Cessation
-
2002
- 2002-07-08 JP JP2003517286A patent/JP2004536616A/ja active Pending
- 2002-07-08 MX MXPA04000651A patent/MXPA04000651A/es not_active Application Discontinuation
- 2002-07-08 EP EP02741568A patent/EP1419257A1/en not_active Withdrawn
- 2002-07-08 CA CA002453372A patent/CA2453372A1/en not_active Abandoned
- 2002-07-08 WO PCT/SE2002/001121 patent/WO2003012112A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
SE518759C2 (sv) | 2002-11-19 |
MXPA04000651A (es) | 2004-10-27 |
EP1419257A1 (en) | 2004-05-19 |
JP2004536616A (ja) | 2004-12-09 |
CA2453372A1 (en) | 2003-02-13 |
WO2003012112A1 (en) | 2003-02-13 |
SE0102627D0 (sv) | 2001-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009009530A (es) | Composiciones de acidos nucleicos cerrados bicatenarios. | |
IN2012DN00403A ( ) | ||
ES2570828T3 (es) | Método de análisis de metilación | |
NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
MY145619A (en) | Oligonucleotide analogues incorporating 5-aza-cytosine therein | |
WO2003086280A3 (en) | Immunostimulatory g,u-containing oligoribonucleotides | |
NZ591416A (en) | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof | |
MX2009012482A (es) | Oligonucleotidos de clase a con potencia inmunoestimuladora. | |
WO2001047944A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
MXPA01010392A (es) | Produccion de vacunas de virus con arn de hebra negativa atenuados a partir de secuencias de nucleotidos clonadas. | |
EA201171131A1 (ru) | Усовершенствованное определение экспрессии генов | |
HK1154623A1 (en) | Isolated luciferases and the use thereof | |
SE0102627L (sv) | Vektorer motståndskraftiga mot metylering | |
EP1209228A3 (en) | Environmental stress responsive promoter | |
ES2286212T3 (es) | Secuencias suprimidas especificamente del genoma de mycobacterium tuberculosis, y su uso en el diagnostico y como vacunas. | |
HK1090663A1 (en) | Chicken rna polymerase i promoter and the use thereof | |
WO2001048245A3 (en) | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof | |
ES2530716T3 (es) | Especies de pestivirus | |
DE60032328D1 (de) | Verfahren zur herstellung von coenzym q 10 | |
EP2053127A3 (en) | Isolated polynucleotides having a reduced or an increased content of epigenetic control motifs and uses thereof | |
NZ505676A (en) | Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins | |
ZA200100332B (en) | Novel nucleotide sequences coding for the ptsH gene. | |
MX2008013416A (es) | Medios para inhibir la expresion de cd31. | |
MXPA02001009A (es) | Virus de la influenza atenuado util como vacuna. | |
AU2001287860A1 (en) | Transglutaminase gene products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |